Shuttle Pharmaceuticals (NASDAQ:SHPH) Shares Down 6.3% – What’s Next?

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH)’s share price was down 6.3% on Tuesday . The stock traded as low as $1.71 and last traded at $1.77. Approximately 70,783 shares traded hands during trading, a decline of 57% from the average daily volume of 164,641 shares. The stock had previously closed at $1.89.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SHPH shares. Weiss Ratings restated a “sell (e)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 15th. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Shuttle Pharmaceuticals Stock Performance

The company has a market cap of $2.71 million, a P/E ratio of -0.14 and a beta of -0.88. The stock has a 50-day moving average of $2.24 and a two-hundred day moving average of $3.26.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share (EPS) for the quarter.

Institutional Trading of Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC acquired a new position in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned approximately 9.40% of Shuttle Pharmaceuticals as of its most recent SEC filing. 4.58% of the stock is currently owned by institutional investors and hedge funds.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .